1 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000
|
2 |
M. Lindenberg, S. Kopp and J.B. Dressman, Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system, Eur. J Pharm. Biopharm., 58, 265-278 (2004)
DOI
ScienceOn
|
3 |
FDA Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms, August 1997
|
4 |
M. Siewert, FIP guidelines for dissolution testing of solid oral products, Pharm. Ind., 57, 362-369 (1995)
|
5 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry - Immediate release solid oral dosage forms; Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995
|
6 |
H. Sah, S.A Park, M.O. Yun and S.J. Kang, Scrutiny made to SUPAC-IR dealing with postapproval changes in immediate release solid oral dosage forms, J. Kor. Pharm. Sci., 34, 57-71 (2004)
|
7 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry - Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlation, September 1997
|
8 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry - SUPAC-MR: Modified release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, September 1997
|
9 |
H.H. Blume and B.S. Schug, The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver, Eur. J Pharm. Biopharm., 9, 117-121 (1999)
|
10 |
식품의약품안전청 고시 제 2002-61호, 의약품동등성시험관리 규정, 2002년 11월
|
11 |
일본국립의약품식품위생연구소(National Institute of Health Sciences), Guideline for bioequivalence studies of generic products, December 1997
|
12 |
일본국립의약품식품위생연구소(National Institute of Health Sciences), Guideline for bioequivalence studies for formulation changes of oral solid dosage forms, February 2000
|